SCCOR in Translational Research in Acute Lung Injury

$3,228,692P50FY2007HLNIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 38950166 Paper 36821369 Paper 36519995 Paper 32343675 Paper 30990758 Paper 30744430 Paper 29237497 Paper 29142002 Paper 28858533 Paper 28708019 Paper 28418697 Paper 26540401 Paper 26536201 Paper 24146959 Paper 23304388 Paper 22876285 Paper 22539080 Paper 21423000 Paper 21136857 Paper 21092115 Paper 20813889 Paper 19901347 Paper 19858233 Paper 19801452 Paper 19654405 Paper 19276240 Paper 19245714 Paper 19204514 Paper 19121672 Paper 19116209 Paper 19028978 Paper 19017887 Paper 18996903 Paper 18852243 Paper 18691101 Paper 18658106 Paper 18652698 Paper 18635889 Paper 18621893 Paper 18434890 Paper 18423191 Paper 18403321 Paper 18198819 Paper 18195024 Paper 18162603 Paper 17803352 Paper 17726014 Paper 17576821 Paper 17446527 Paper 17397009 Paper 17114483 Paper 17076839 Paper 16995930 Paper 16980879 Paper 16936244 Paper 16855596 Paper 16816363 Paper 16712726 Paper 16632110 Paper 16548523 Paper 16542223 Paper 16363993 Paper 16322590 Paper 16224105 Paper 16222040 Paper 16116230 Paper 16081831 Paper 16024722 Paper 15983040 Paper 15967795 Paper 15845656 Paper 15713736 Paper 15655784 Paper 15629862 Paper 15574409 Paper 15326314 Paper 15292179 Paper 15239833 Paper 14871871

Abstract

DESCRIPTION (provided by applicant): The overall objective of this application for a Specialized Center of Clinical Research is to investigate novel aspects of the pathogenesis and treatment of acute lung injury in humans. Acute lung injury is an important clinical problem in critically ill patients that affects more than 100,000 patients annually in the United States. Our major hypothesis is that new advances in understanding pathogenesis and treatment will come from research approaches that take into account the complexity of biological responses in humans. Past approaches to this disease have emphasized single pathways in pathogenesis and treatment, but recent developments in biotechnology have made it possible to approach lung injury from a systems point of view that recognizes the importance of multiple pathways in the injury and repair process. Our application brings together a cohesive group of six projects (three clinical and three basic) and three cores, Administrative, Biotechnology, and Educational. Project 1 will investigate the complexity of host determinants of inflammatory responses in normal and critically ill patients; Project 2 will perform a randomized trial of a new treatment program in survivors of acute lung injury, recognizing the complex clinical needs of these patients; Project 3 will perform pilot projects of new treatments with the aim of taking forward positive results to larger clinical trials; Project 4 investigates the complex early interactions between bacteria and the alveolar environment that influence bacterial pathogenesis; Project 5 investigates a novel new pathway that protects mice from systemic sepsis; and Project 6 investigates the complex mechanisms that control alveolar epithelial injury. The proposed studies evolve logically from ongoing studies in the current Seattle ARDS Research Program. The proposed SCCOR Program will enhance understanding of the pathogenesis of lung injury and could lead to new treatments and improved long-term outcome for patients with acute lung injury.

View original record on NIH RePORTER →